Novartis (NVS) said Wednesday that the European Commission has approved its drug Kisqali in combination with an aromatase inhibitor as an adjuvant treatment for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer at high risk of recurrence.
The approval of the drug, also called ribociclib, is based on results from a 20-country, 5,101-patient phase III trial which showed a 25.1% reduction in risk of disease recurrence compared with endocrine therapy alone, the company said.
The news follows the recent US Food and Drug Administration approval of Kisqali for early breast cancer patients, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。